App-Quantinova.ai

Tumor necrosis factor alpha, a neurotoxic proinflammatory cytokine for oxaliplatin-induced peripheral neuropathy.

Zohreh Ghoreishi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral neuropathy

ILS-969

CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC).

Ryan JO Dowling - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Metformin Hydrochloride

Endothelial dysfunction in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study.

Daniel A. Mulrooney - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Fibrinogen (IV)

Evaluation of cardiovascular health in sarcoma survivors.

Laurence H. Baker - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Association of high-sensitivity C-reactive protein with health-related quality of life among breast cancer survivors

Hyun Jeong Cho - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ergocalciferol

Crown-like structures and adipocyte size in fat tissue adjacent to breast tumor reflect parameters of obesity, dyslipidemia and serum high-sensitivity C-reactive protein

Charlotte Vaysse - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colon rectal cancer: Results from the ITACa trial.

Andrea Casadei Gardini - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

POWER-remote: A randomized study evaluating the effect of a remote-based weight loss program on biomarkers in women with early-stage breast cancer.

Cesar Augusto Santa-Maria - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Zoledronic acid

Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA study

S. Lee - European Crohn’s and Colitis Organisation (ECCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Anti-MAdCAM antibody

Fecal Calprotectin is a valuable marker for detecting active Crohn`s disease with colon involvement

X. Ga - European Crohn’s and Colitis Organisation (ECCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Utility of post-induction trough level measurement in planning infliximab maintenance therapy for pediatric IBD

P.C. Churc - European Crohn’s and Colitis Organisation (ECCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

Infliximab

Efficacy of Exclusive Enteral Nutrition (EEN) in Active Crohns Disease with Complications or Failure of Medical Treatment

Q. Yang - European Crohn’s and Colitis Organisation (ECCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

Early hs-CRP normalization and mucosal healing are effective predictors for 1-year mucosal healing

X. Ga - European Crohn’s and Colitis Organisation (ECCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

Infliximab

Adalimumab induction therapy achieves clinical remission and response in chinese patients with Crohn's Disease

Z.H. Ran - European Crohn’s and Colitis Organisation (ECCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Adalimumab

Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: Pooled Analysis from ULTRA 1 and ULTRA 2

W.J. Sandborn - European Crohn’s and Colitis Organisation (ECCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Inflammatory bowel disease

Adalimumab

Influence of Disease Course on Therapeutic Effect of IFX in Crohn's disease

X. Ga - European Crohn’s and Colitis Organisation (ECCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Modifiable metabolic markers c-peptide (C-PEP), highly sensitive c-reactive protein (hsCRP), leptin (LEP)] and lung cancer (LC) risk: A matched case-control study nested in the prostate, lung, colorectal and ovarian (PLCO) cancer screening study.

Pamela Jean Goodwin - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Lung Cancer

N/A

Both metabolic syndrome and statin use are more common in women with breast inflammation

Iyengar NM - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Metabolic syndrome

N/A

Post-surgical highly sensitive C-reactive protein (hsCRP) and prognosis in early stage in breast cancer (BC).

Ariadna Tibau Martorell - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).

Pamela Jean Goodwin - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Metformin Hydrochloride

Filters

1408 Abstracts